EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Zoledronate Sequential Therapy After Denosumab Discontinuation to Prevent Bone Mineral Density Reduction

Chia-Che Lee, Chen-Yu Wang, Hung-Kuan Yen, Chih-Chien Hung, Cheng-Yo Lai, Ming-Hsiao Hu, Ting-Ming Wang, Chung-Yi Li, Shau-Huai Fu

JAMA Network Open · 11.11.2024 · 7 (11) · e2443899

DOI: 10.1001/jamanetworkopen.2024.43899 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 11.11.2024. Verfasst von Chia-Che Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Zoledronic Acid, Denosumab, Bone Density Conservation Agents, Bone Density. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Discontinuation of denosumab without transitioning to another antiresorptive agent results in rapid bone loss and an increased risk of fracture. Previous randomized studies reported inconsistent results regarding the efficacy of zoledronate as sequential therapy.

Objective

To investigate the use of sequential therapy with zoledronate to prevent bone loss and decreased bone mineral density (BMD) after denosumab discontinuation in the first year. Design, Setting, and Participants The Denosumab Sequential Therapy prospective, open-label, parallel-group randomized clinical trial was conducted at a referral center and 2 affiliated hospitals in Taiwan. Recruitment was conducted from April 1, 2019, to May 31, 2021, and a 2-year follow-up was planned. The trial included postmenopausal women and men aged 50 years or older who received regular denosumab treatment for at least 2 years and did not have previous exposure to other antiosteoporosis medication or meet other exclusion criteria.

Intervention

Participants were assigned via stratified randomization to 1 of 2 groups: group A received continuous denosumab treatment (60 mg twice yearly) as the positive control, whereas group ZOL received 1 dose of zoledronate (5 mg) in the first year. Main Outcomes and Measures The coprimary outcomes were BMD percentage changes in the lumbar spine (LS-BMD), total hip (TH-BMD), and femoral neck (FN-BMD), respectively. An intention-to-treat analysis was performed.

Results

This study included 101 patients (95 women [94.1%]; median age, 72.0 [IQR, 67.0-76.0] years). There were 25 patients in group A (23 women [92.0%]; median age, 74.0 [IQR, 70.0 to 78.0] years) and 76 in group ZOL (72 women [94.7%]; median age, 71.0 [IQR, 65.7 to 76.0] years). In the first year, group ZOL had a significant median decrease in LS-BMD (−0.68% [IQR, −3.22% to 2.75%]) compared with group A (1.30% [IQR, −0.68% to 5.24%]) ( P = .03). No significant differences between groups A and ZOL were observed for TH-BMD (median, 1.12% [IQR, −0.06% to 2.25%] vs 0% [−1.47% to 2.15%]) ( P = .24) and FN-BMD (median, 0.17% [IQR, −2.29% to 2.90%] vs 0.18% [−2.73% to 3.88%]) ( P = .71). We observed a significant difference in the median LS-BMD percentage change for the ZOL subgroup with 3 or more years of denosumab treatment before enrollment (−3.20% [IQR, −7.89% to 0.68%]) compared with group A (1.30% [IQR, −0.68% to 5.24%]) ( P = .003). Conclusions and Relevance In this randomized trial of sequential therapy after denosumab discontinuation, bone loss was observed in LS-BMD in the first year among patients receiving zoledronate. A longer duration of denosumab treatment was associated with a further decrease in LS-BMD after zoledronate sequential therapy. Further randomized clinical trials and large-scale studies that investigate the strategies of sequential therapy after long-term denosumab treatment are needed. Trial Registration ClinicalTrials.gov Identifier: NCT03868033

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zoledronic AcidDenosumabBone Density Conservation AgentsBone DensityHumansFemaleAgedMaleMiddle AgedProspective StudiesOsteoporosisTaiwan

Substanzen

Zoledronic AcidDenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, National Taiwan University Hospital, Taipei, Taiwan.
  • Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan.
  • National Center for Geriatrics and Welfare Research, National Health Research Institutes, Yunlin, Taiwan.
  • Department of Pharmacy, National Taiwan University Hospital Yunlin Branch, Douliu, Taiwan.
  • Department of Orthopedics, National Taiwan University Hospital Yunlin Branch, Douliu, Taiwan.
  • Department of Orthopaedic Surgery, National Taiwan University Hospital, Hsinchu, Taiwan.

Zitieren

APA

Lee, C. C., Wang, C. Y., Yen, H. K., Hung, C. C., Lai, C. Y., Hu, M. H., Wang, T. M., Li, C. Y., & Fu, S. H. (2024). Zoledronate Sequential Therapy After Denosumab Discontinuation to Prevent Bone Mineral Density Reduction. JAMA Network Open, 7(11), e2443899. https://doi.org/10.1001/jamanetworkopen.2024.43899

Vancouver

Lee CC, Wang CY, Yen HK, Hung CC, Lai CY, Hu MH, et al. Zoledronate Sequential Therapy After Denosumab Discontinuation to Prevent Bone Mineral Density Reduction. JAMA Network Open. 2024;7(11):e2443899. doi:10.1001/jamanetworkopen.2024.43899

BibTeX
@article{Lee2024,
  author = {Lee, Chia-Che and Wang, Chen-Yu and Yen, Hung-Kuan and Hung, Chih-Chien and Lai, Cheng-Yo and Hu, Ming-Hsiao and Wang, Ting-Ming and Li, Chung-Yi and Fu, Shau-Huai},
  title = {Zoledronate Sequential Therapy After Denosumab Discontinuation to Prevent Bone Mineral Density Reduction},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {11},
  pages = {e2443899},
  doi = {10.1001/jamanetworkopen.2024.43899}
}
Kostenlos starten →